Alan S Kliger, MD
he/him/his
DownloadHi-Res Photo
About
Biography
Dr. Kliger is Clinical Professor of Medicine, Yale School of Medicine. He served as Sr. VP Medical Affairs for Yale New Haven Health System, and was its Chief Quality Officer. He also served the Hospital of St. Raphael, New Haven as Chairman of the Department of Medicine, and later its Chief Medical Officer. Dr. Kliger currently serves as the Chair of the American Society of Nephrology's Excellence in Patient Care Advisory Committee. Dr. Kliger has co-authored more than 190 publications in peer-reviewed journals, with particular interest in dialysis, quality measurement, quality improvement and patient safety.
Appointments
Internal Medicine
Clinical ProfessorPrimary
Other Departments & Organizations
Education & Training
- MD
- SUNY Upstate Med Center (1970)
- BS
- City College of New York (1966)
Board Certifications
Nephrology
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 1976
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 1973
Research
Overview
Clinical research in areas of chronic kidney disease, hemo- and peritoneal dialysis, quality measures, quality improvement, patient safety
ORCID
0000-0002-9103-477X
Research at a Glance
Yale Co-Authors
Frequent collaborators of Alan S Kliger's published research.
Publications Timeline
A big-picture view of Alan S Kliger's research output by year.
Karl Insogna, MD, FACP
Arthur Rosenfield, MD
John Wysolmerski, MD
Margaret Fikrig, MD
Fredric Finkelstein
Clare McGarvey Lambert, MD
57Publications
2,535Citations
Publications
2024
Human Factors Contributing to Infection Prevention in Outpatient Hemodialysis Centers: A Mixed Methods Study
Parker S, Jesso M, Wolf L, Leigh K, Booth S, Gualandi N, Garrick R, Kliger A, Patel P. Human Factors Contributing to Infection Prevention in Outpatient Hemodialysis Centers: A Mixed Methods Study. American Journal Of Kidney Diseases 2024, 84: 18-27. PMID: 38447708, PMCID: PMC11193600, DOI: 10.1053/j.ajkd.2023.12.024.Peer-Reviewed Original ResearchCitationsAltmetricConceptsInfection preventionMultidisciplinary teamDialysis facilitiesMixed methods studyOutpatient hemodialysis centersOutpatient dialysis facilitiesOutpatient dialysis settingInfection prevention effortsOutpatient dialysis centersDialysis centersOutpatient careStaff conversationsMethods studyPrevention effortsStaff encounterDialysis settingAxial codingPrevention barriersAbstractText Label="RATIONALEMacroergonomic approachWork system designHemodialysis centersPreventionSample sizeQuantitative data
2023
Approaches to Maximize Safety for Patients with Kidney Diseases after the End of COVID-19 Public Health Emergency
Silberzweig J, Kliger A, White D, Stark S, Kumar V. Approaches to Maximize Safety for Patients with Kidney Diseases after the End of COVID-19 Public Health Emergency. Clinical Journal Of The American Society Of Nephrology 2023, 19: 263-265. PMID: 37642955, PMCID: PMC10861095, DOI: 10.2215/cjn.0000000000000303.Peer-Reviewed Original ResearchAltmetricEffects of Spironolactone on Arrhythmias in Hemodialysis Patients: Secondary Results of the SPin-D Randomized Controlled Trial
Mc Causland F, Hsu J, Himmelfarb J, Ikizler T, Raj D, Mehrotra R, Waikar S, Kimmel P, Kliger A, Dember L, Charytan D, Kliger A, Charytan D, Mc Causland F, Robinson E, Waikar S, Williams M, Weiner D, Aurien-Blajeni E, Cinelli M, Nizam T, Rim S, Seok P, Smith C, Curtis J, Raj D, Regunathan-Shenk R, Sharma S, Ramezani A, Andrews S, Dumadag M, Franco C, Wing M, Himmelfarb J, Mehrotra R, Anderson L, Linke L, Manahan L, Ikizler T, Hung A, Cavanaugh K, Booker C, Brannon B, Clagett A, Ellis C, Dember L, Landis J, Anderson A, Hsu J, Cifelli D, Ballard S, Durborow M, Howard T, Kuzla N, Nessel L, Tierney A, Skali H, Solomon S, Rad A, Di Carli M, Gaber M, Foster C, Kimmel P, Kusek J. Effects of Spironolactone on Arrhythmias in Hemodialysis Patients: Secondary Results of the SPin-D Randomized Controlled Trial. Kidney360 2023, 4: e486-e495. PMID: 36763641, PMCID: PMC10278797, DOI: 10.34067/kid.0000000000000067.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsEffect of spironolactoneFrequency of bradycardiaMaintenance hemodialysisFollow-upPost hoc analysisConduction blockArrhythmic eventsCardiovascular eventsMaintenance HDSudden deathHoc analysisIncidence of cardiovascular eventsAssociation of spironolactoneDose of spironolactoneRisk of cardiovascular eventsDouble-blind trialProportion of patientsPatients treated with maintenance HDRandomized controlled trialsGeneralized estimating equation modelsSpironolactone groupPlacebo-controlledSpironolactone treatmentBradycardic eventsAge of participantsSome Lessons Learned for Kidney Failure Patients in the COVID-19 Pandemic
Kliger A, Silberzweig J, McNamara E, Stark S. Some Lessons Learned for Kidney Failure Patients in the COVID-19 Pandemic. Clinical Journal Of The American Society Of Nephrology 2023, 18: 946-948. PMID: 36723343, PMCID: PMC10356111, DOI: 10.2215/cjn.0000000000000090.Peer-Reviewed Original ResearchCitationsAltmetricKidney Transplant Practice in Pandemic Times
Kumar V, Leigh K, Kliger A, Roberts G, Mohan S, Leca N, Sawinski D, Josephson M, Mannon R, Lentine K. Kidney Transplant Practice in Pandemic Times. Clinical Journal Of The American Society Of Nephrology 2023, 18: 961-964. PMID: 36795033, PMCID: PMC10356143, DOI: 10.2215/cjn.0000000000000092.Peer-Reviewed Original ResearchCitationsAltmetric54 COVID-19 and Dialysis Patients
Silberzweig J, Kliger A. 54 COVID-19 and Dialysis Patients. 2023, 491-496. DOI: 10.1016/b978-0-323-79135-9.00054-9.ChaptersConceptsDialysis therapyIntermittent renal replacement therapyCOVID-19Continuous dialysis therapyAcute kidney injuryChronic kidney diseaseRenal replacement therapyAcute peritoneal dialysisAssociated risk factorsHome dialysis therapiesHigh rateDepartment of HealthKidney injuryDiabetes mellitusDialysis patientsFacility patientsPeritoneal dialysisKidney diseaseReplacement therapyDialysis programRisk factorsSevere diseaseMedical conditionsSubstantial burdenPatients
2022
A randomized controlled pilot trial of anakinra for hemodialysis inflammation
Dember L, Hung A, Mehrotra R, Hsu J, Raj D, Charytan D, Mc Causland F, Regunathan-Shenk R, Landis J, Kimmel P, Kliger A, Himmelfarb J, Ikizler T, Consortium H. A randomized controlled pilot trial of anakinra for hemodialysis inflammation. Kidney International 2022, 102: 1178-1187. PMID: 35863559, PMCID: PMC9588554, DOI: 10.1016/j.kint.2022.06.022.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPatient-reported outcomesPlacebo groupAdverse eventsMedian decreaseHemodialysis patientsIL-6IL-1 receptor antagonistRate of adverse eventsEffect of anakinraPlacebo-controlled trialBaseline to weekAnti-cytokine therapyIL-1 inhibitionAssociated with morbidityAnakinra groupReceptor antagonistBetween-group differencesEfficacy outcomesAnakinraMaintenance hemodialysisRandomized controlled pilot trialChronic inflammationEvaluate safetyPlaceboIL-1Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease
Tuttle KR, Wong L, St. Peter W, Roberts G, Rangaswami J, Mottl A, Kliger A, Harris RC, Gee PO, Fowler K, Cherney D, Brosius FC, Argyropoulos C, Quaggin SE. Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease. Clinical Journal Of The American Society Of Nephrology 2022, 17: 1092-1103. PMID: 35649722, PMCID: PMC9269635, DOI: 10.2215/cjn.02980322.Commentaries, Editorials and LettersCitationsAltmetricMeSH Keywords and ConceptsConceptsDiabetic kidney diseaseKidney disease careKidney diseaseHealth care systemDisease careKidney failureGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsPeptide-1 receptor agonistsAngiotensin-converting enzyme inhibitorBreakthrough therapiesMajor public health challengeHealth care system supportCare systemAngiotensin receptor blockersCotransporter 2 inhibitorsHalf of patientsPocket drug costsIndividual health care systemsPublic health challengeHealth care professionalsValue-based careEligible patientsMineralocorticoid antagonistsCardiovascular events
2021
Transforming the Care of Patients with Diabetic Kidney Disease
Brosius FC, Cherney D, Gee PO, Harris RC, Kliger A, Tuttle KR, Quaggin SE. Transforming the Care of Patients with Diabetic Kidney Disease. Clinical Journal Of The American Society Of Nephrology 2021, 16: 1590-1600. PMID: 34103350, PMCID: PMC8499007, DOI: 10.2215/cjn.18641120.Commentaries, Editorials and LettersCitationsAltmetricMeSH Keywords and ConceptsConceptsRenin-angiotensin system inhibitorsDiabetic kidney diseaseIrbesartan Diabetic Nephropathy TrialCare of patientsKidney diseaseSystem inhibitorsNew therapiesAngiotensin II Antagonist Losartan (RENAAL) trialAngiotensin II type 1 receptor blockerDiabetic kidney disease progressionType 1 receptor blockerCardiovascular protective therapiesReduction of EndpointsKidney disease progressionKidney protective effectsRenin-angiotensin systemDiabetic Nephropathy TrialRisk of deathHigh residual riskHealth care providersPowerful new therapiesNephropathy TrialReceptor blockersDevastating complicationAntihypertensive agentsSARS-CoV-2 Antibody Dynamics in Chronic Hemodialysis Patients
Thwin O, Grobe N, Ye X, Preciado P, Silva L, Cherif A, Wang Y, Kshirsagar A, Kliger A, Finkelstein F, Kotanko P. SARS-CoV-2 Antibody Dynamics in Chronic Hemodialysis Patients. Journal Of The American Society Of Nephrology 2021, 32: 770-770. DOI: 10.1681/asn.20213210s1770b.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
activity NIH / NIDDK Steering Committee for Consortium: Hemodialysis Novel Therapies (HDNT)
Professional OrganizationsChairDetails2014 - Presenthonor Journal of the American Society of Nephrology Reviewer of the Year
National AwardAmerican Society of NephrologyDetails11/02/2023United Statesactivity National Quality Forum Renal Standing Committee
Professional OrganizationsMemberDetailsNational Quality Organization reviewing and recommending measures for quality care06/01/2014 - 07/01/2023activity National Quality Forum, Renal Standing Committee
Professional OrganizationsMemberDetails07/01/2014 - 07/01/2023activity NIH / NIDDK Steering Committee for Consortium: Hemodialysis Novel Therapies (HDNT)
Professional OrganizationsChairDetails2014 - 2022
News
News
- January 10, 2022Source: Propublica
They Were The Pandemic’s Perfect Victims
- October 14, 2020
Thank You Voluntary Faculty
- September 30, 2020Source: HCP Live
Alan S. Kliger, MD: Negative COVID-19 Outcomes Common in Kidney Disease Patients
- August 23, 2020Source: The Philadelphia Inquirer
The coronavirus is damaging kidneys. Doctors worry that some survivors will need dialysis forever.
Get In Touch
Contacts
Mailing Address
Yale School of Medicine
61 Rock Hill Road
Woodbridge, CT 06525
United States